Argenx heads for worst day in nearly 3 yrs after ending drug study

argenx SE

08/10/2026 08:42

** Shares in Argenx ARGX.BR  fall around 16% after the Belgian-Dutch immunology company discontinued a drug study for an autoimmune disorder, Sjogren’s, saying it was unable to meet the endpoint
** KBC Securities trims is PT on the stock by 5% to €950, but keeps its "buy" rating
** The company reported positive results from phase 2 study of FB102 in celiac disease 
** "We view the Sjögren’s negative outcome as a small setback and consider the early celiac success as a more important proof for argenx’s BD capabilities," Kempen Daily says
** Stock at its lowest price since early June; if losses hold, it will see its biggest one-day drop since December 2023
     
     

(Reporting by Margaux Perrin in Gdansk)
((Margaux.Perrin@thomsonreuters.com ))